Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Listì

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Oncotarget|February 27, 2016
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Cancer Treatment Reviews|July 14, 2021
Repositioning PARP inhibitors in the treatment of thoracic malignanciesFrancesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, et al.
Expert Opinion on Biological Therapy|September 12, 2015
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Francesco Passiglia, Giuseppe Bronte, Marta Castiglia, et al.
Translational Cancer Research|February 4, 2022
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancerAngela Listì, Nadia Barraco, Marco Bono, et al.
Scientific Reports|September 8, 2018
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Cellular Immunology|February 4, 2018
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, et al.
Scientific Reports|November 20, 2018
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Cancer|March 11, 2023
Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapyPaolo Bironzo, Massimiliano Cani, Francesca Jacobs, et al.
Oncotarget|January 6, 2017
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsLorena Incorvaia, Francesc Passiglia, Sergio Rizzo, et al.
Oncotarget|July 31, 2016
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathwayDaniela Massihnia, Antonio Galvano, Daniele Fanale, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Oncotarget|February 27, 2016
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Cancer Treatment Reviews|July 14, 2021
Repositioning PARP inhibitors in the treatment of thoracic malignanciesFrancesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, et al.
Expert Opinion on Biological Therapy|September 12, 2015
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Francesco Passiglia, Giuseppe Bronte, Marta Castiglia, et al.
Translational Cancer Research|February 4, 2022
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancerAngela Listì, Nadia Barraco, Marco Bono, et al.
Scientific Reports|September 8, 2018
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Cellular Immunology|February 4, 2018
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, et al.
Scientific Reports|November 20, 2018
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Cancer|March 11, 2023
Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapyPaolo Bironzo, Massimiliano Cani, Francesca Jacobs, et al.
Oncotarget|January 6, 2017
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsLorena Incorvaia, Francesc Passiglia, Sergio Rizzo, et al.
Oncotarget|July 31, 2016
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathwayDaniela Massihnia, Antonio Galvano, Daniele Fanale, et al.
Pageof 4